IP Library › Granted Patent US 12,454,578
Granted Patent B2
US 12,454,578 · App. 17/746,642 · Granted Oct 28, 2025

Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors

Inventors: Martin Pulé (London, GB); Shaun Cordoba (London, GB); Simon Thomas (London, GB); Shimobi Onuoha (London, GB); Mathieu Ferrari (London, GB); Wen Chean Lim (London, GB); Biao Ma (London, GB)
Assignee: AUTOLUS LIMITED
C07K16/2878A61K40/11A61K40/31A61K40/4211A61K40/4215A61P35/00C07K16/2803C12N5/0636A61K2239/28C07K2317/31C07K2317/55C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,454,578
App. No.
17/746,642
Granted
Oct 28, 2025
Kind
B2
Abstract

The present invention provides a chimeric antigen receptor (CAR) which binds a low density target antigen, which comprises a Fab antigen binding domain. The invention also relates to cells expressing such a CAR and their use in the treatment of disease.

Claims (6)

1. A cytolytic immune cell which expresses:

a) a first chimeric antigen receptor (CAR) which binds B cell maturation antigen (BCMA), wherein the BCMA CAR comprises a Fab antigen binding domain comprising the VH domain of SEQ ID NO: 29 and the VL domain of SEQ ID NO: 30; and

b) a second CAR which binds CD19, wherein the CD19 CAR comprises an scFv comprising the VH domain of SEQ ID NO: 67 and the VL domain of SEQ ID NO: 75.

2. A method for making a cell according to claim 1 , which comprises the step of introducing a nucleic acid or nucleic acids which express the CARs into a cell ex vivo.

3. A pharmaceutical composition which comprises a plurality of cells according to claim 1 , together with a pharmaceutically acceptable carrier, diluent or excipient.

4. A method for treating multiple myeloma which comprises the step of administering a pharmaceutical composition according to claim 3 to a subject.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: PULÉ, MARTIN; CORDOBA, SHAUN; THOMAS, SIMON; ONUOHA, SHIMOBI; LIM, WEN CHEAN; MA, BIAO; FERRARI, MATHIEU
To: AUTOLUS LIMITED
Reel/Frame 061321/0045 →
Priority Claims (2)
GB 1815775 · Sep 27, 2018 · national
GB 1902021 · Feb 14, 2019 · national
Continuity (2)
Continuation 17279874
Related Publication 20220356260A1 · Nov 10, 2022
References Cited (67)
US 10160794B2 · Pule et al. · 2018 [cited by applicant]
US 10294304B2 · Kuo et al. · 2019 [cited by applicant]
US 10919951B2 · Pule et al. · 2021 [cited by applicant]
US 11058722B2 · Pulé et al. · 2021 [cited by applicant]
US 12049510B2 · Pulé · 2024 [cited by examiner]
US 20070071675A1 · Wu et al. · 2007 [cited by applicant]
US 20160200813A1 · Benatuil et al. · 2016 [cited by applicant]
US 20160237139A1 · Pule et al. · 2016 [cited by applicant]
US 20170362297A1 · Marasco · 2017 [cited by applicant]
US 20180147271A1 · Morgan et al. · 2018 [cited by applicant]
US 20190100571A1 · Pule et al. · 2019 [cited by applicant]
US 20210101959A1 · Pule et al. · 2021 [cited by applicant]
US 20210130496A1 · Chang · 2021 [cited by examiner]
US 20230074436A1 · Guo et al. · 2023 [cited by applicant]
US 20240076352A1 · Pule et al. · 2024 [cited by applicant]
CN 105777911A · 2016 [cited by applicant]
CN 107406518A · 2017 [cited by applicant]
CN 107980046A · 2018 [cited by applicant]
KR 20170037626A · 2017 [cited by applicant]
WO WO0177342A1 · 2001 [cited by applicant]
WO WO2009114585A1 · 2009 [cited by applicant]
WO WO2013154760A1 · 2013 [cited by applicant]
WO WO2015052538A1 · 2015 [cited by applicant]
WO WO2015069922A2 · 2015 [cited by applicant]
WO WO2015075469A1 · 2015 [cited by applicant]
WO WO2015075470A1 · 2015 [cited by applicant]
WO WO2015150771A1 · 2015 [cited by applicant]
WO WO2016014565A2 · 2016 [cited by applicant]
WO WO2016014789A2 · 2016 [cited by applicant]
WO WO2016030691A1 · 2016 [cited by applicant]
WO WO2016094304A2 · 2016 [cited by applicant]
WO WO2016100985A2 · 2016 [cited by applicant]
WO WO2016102965A1 · 2016 [cited by applicant]
WO WO2016090337A1 · 2016 [cited by applicant]
WO WO2016124930A1 · 2016 [cited by applicant]
WO WO2016151315A1 · 2016 [cited by applicant]
WO WO2016139487A1 · 2016 [cited by examiner]
WO WO2016201300A1 · 2016 [cited by applicant]
WO WO2017029511A1 · 2017 [cited by applicant]
WO WO2017029512A1 · 2017 [cited by applicant]
WO WO2017072361A1 · 2017 [cited by applicant]
WO WO2017156479A1 · 2017 [cited by applicant]
WO WO2017173349A1 · 2017 [cited by applicant]
WO WO2019075395A1 · 2019 [cited by examiner]
WO WO2019090003A1 · 2019 [cited by applicant]
WO WO2019150133A1 · 2019 [cited by applicant]
WO WO2020018825A1 · 2020 [cited by applicant]
Carpenter et al., “B-cell Muturation Antigen Is a Promising Target for Adoptive T-cell Therapy to Multiple Myeloma,” Clin Cancer Res 19(8):2048-60 (2013). [cited by applicant]
Donnelly et al., “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,” Journal of General Virology 82:1027-1041 (2001). [cited by applicant]
Fry et al., “CD22-CAR T Cells Induce Remissions in CD19-CAR Naive and Resistant B-ALL,” Nat. Med. 24(1):20-28 (2018). [cited by applicant]
Huang et al., “IGF1R- and ROR1-Specific Car T Cells as a Potential Therapy for High Risk Sarcomas,” PLOS One 10(7):18 pages (2015). [cited by applicant]
Hymowitz et al., “Structures of APRIL-Receptor Complexes,” The Journal of Biological Chemistry, 280(8):7218-7227 (2005). [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/GB2019/052726 dated Apr. 8, 2020. [cited by applicant]
Nolan et al., “Bypassing Immunization: Optimized Design of “Designer T Cells” against Carcinoembryonic Antigen (CEA)-expressing Tumors, and Lack of Suppression by Soluble CEA,” Clinical Cancer Research 5:3928-3941 (1999… [cited by applicant]
Peng et al., “Mining Naive Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility,” J Mol Biol 429(19):2954-2973 (2017). [cited by applicant]
Walker et al., “Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase,” Mol. Ther. 25:2189-2201 (2017). [cited by applicant]
Yang et al., “Therapeutic Potential and Challenges of Targeting Receptor Tyrosie Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies,” PLOS One 6(6), 15 pages (2011). [cited by applicant]
Brunner T., et al., “Cytotoxic T cells: Double-Barreled Shot Guns,” Nature Medicine, Abstract, vol. 5, No. 1, 1999, pp. 20. [cited by applicant]
Koiko P., et al., “Immunology,” Translated from English, Edited by Serebryanoy N.B., Moscow, Academy, 2008, pp. 37. [cited by applicant]
Pan et al., “Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth”, Cancer Cell, 11:53-67 (2007). [cited by applicant]
Roitt et al., “Immunology”, Moscow, pp. 110-111 (2000). [cited by applicant]
Singer et al., “Genes and Genomes”, Moscow, 1:63-64 (1998). [cited by applicant]
Friedman K.M., et al., “Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells”, Human Gene Therapy, 2018, vol.… [cited by applicant]
Sequence Alignment of BDB23358 with instant SEQ ID No. 29. Search Conducted on Feb. 26, 2024, 2 pages. [cited by applicant]
Sequence Alignment of BJB94750 with instant SEQ ID No. 30. Search Conducted on Feb. 26, 2024, 2 pages. [cited by applicant]
Sequence Alignment of SEQ ID No. 40 of U.S. Patent Application Publication No. 2023/0074436 with instant SEQ ID No. 30, Search Conducted on Feb. 26, 2024, 1 page. [cited by applicant]
Sequence Alignment of SEQ ID No. 76 of U.S. Patent Application Publication 2016/0200813 with instant SEQ ID No. 29. Search Conducted on Feb. 26, 2024, 1 page. [cited by applicant]